abrdn Life Sciences Investors (NYSE:HQL) Short Interest Update

abrdn Life Sciences Investors (NYSE:HQL) was the recipient of a significant decline in short interest in January. As of January 30th, there was short interest totaling 37,925 shares, a decline of 37.6% from the January 15th total of 60,767 shares. Based on an average daily trading volume, of 113,249 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.1% of the company’s stock are sold short. Approximately 0.1% of the company’s stock are sold short. Based on an average daily trading volume, of 113,249 shares, the days-to-cover ratio is currently 0.3 days.

abrdn Life Sciences Investors Stock Up 1.0%

Shares of abrdn Life Sciences Investors stock traded up $0.17 on Friday, hitting $16.96. The company had a trading volume of 149,342 shares, compared to its average volume of 115,091. The stock has a 50-day moving average of $16.95 and a 200-day moving average of $15.94. abrdn Life Sciences Investors has a twelve month low of $10.55 and a twelve month high of $17.80.

abrdn Life Sciences Investors Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Friday, February 20th will be paid a $0.56 dividend. This represents a $2.24 dividend on an annualized basis and a yield of 13.2%. The ex-dividend date of this dividend is Friday, February 20th. This is a boost from abrdn Life Sciences Investors’s previous quarterly dividend of $0.50.

Institutional Trading of abrdn Life Sciences Investors

Hedge funds and other institutional investors have recently modified their holdings of the company. Geneos Wealth Management Inc. boosted its position in shares of abrdn Life Sciences Investors by 200.1% during the second quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock worth $29,000 after buying an additional 1,529 shares during the period. Global Retirement Partners LLC lifted its stake in abrdn Life Sciences Investors by 187.8% in the 4th quarter. Global Retirement Partners LLC now owns 7,039 shares of the company’s stock valued at $118,000 after acquiring an additional 4,593 shares in the last quarter. Cornerstone Advisors LLC acquired a new position in abrdn Life Sciences Investors during the 3rd quarter worth approximately $175,000. Stephens Inc. AR grew its stake in shares of abrdn Life Sciences Investors by 9.8% during the 2nd quarter. Stephens Inc. AR now owns 21,231 shares of the company’s stock worth $272,000 after acquiring an additional 1,895 shares in the last quarter. Finally, Samalin Investment Counsel LLC grew its stake in shares of abrdn Life Sciences Investors by 6.7% during the 2nd quarter. Samalin Investment Counsel LLC now owns 21,782 shares of the company’s stock worth $279,000 after acquiring an additional 1,366 shares in the last quarter. Institutional investors and hedge funds own 32.21% of the company’s stock.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.